DELIVEREX
LIVE

Serial Number

79282940

Owner

Evox Therapeutics Limited

Attorney

Bryce J. Maynard

Filing Date

Jan 31, 2020

Add to watchlist:

No watchlists yet
View on USPTO

DELIVEREX Trademark

Serial Number: 79282940 • Registration: 6405652

DELIVEREX is a trademark filed by Evox Therapeutics Limited on January 31, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Evox Therapeutics Limited (10 trademarks)

Oxford Science Park, Medawar Centre,

Entity Type: 99

Trademark Details

Filing Date

January 31, 2020

Registration Date

July 6, 2021

Published for Opposition

April 20, 2021

Goods & Services

Pharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered and purified exosomes in the form of a liquid solution and lyophilised preparation for therapeutic use in the nature of treatment of for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy; Medicine for treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; mixed biological preparations for the prevention and treatment of infectious diseases; EV-based nucleic acid therapeutics in the nature of pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars, and therapeutics for the prevention and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strains and tears, ligament strains and tears, muscle atrophy, and muscular dystrophy

Medical services; medical and pharmaceutical consultancy; medical services relating to the diagnosis and treatment of persons; medical analysis service relating to the diagnosis and treatment of persons provided by medical laboratories; medical analysis and examinations for the diagnosis of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, rare diseases, genetic diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Dec 4, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 23, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 1, 2021 FICS
FINAL DISPOSITION PROCESSED
Nov 1, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 6, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 6, 2021 R.PR
LIMITATION FROM THE IB EXAMINED AND ENTERED
May 4, 2021 LIME
LIMITATION OF GOODS RECEIVED FROM IB
May 1, 2021 LIMG
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 20, 2021 NPUB
PUBLISHED FOR OPPOSITION
Apr 20, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Apr 18, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 31, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 31, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 31, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 13, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 13, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 13, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 13, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 13, 2021 CNEA
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 6, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 6, 2021 GNSL
SUSPENSION LETTER WRITTEN
Mar 6, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 28, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 28, 2021 CRFA
ASSIGNED TO LIE
Jan 27, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 16, 2020 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Jul 30, 2020 NREP
REFUSAL PROCESSED BY IB
May 29, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 14, 2020 RFCS
REFUSAL PROCESSED BY MPU
May 14, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 30, 2020 RFCR
NON-FINAL ACTION WRITTEN
Apr 29, 2020 CNRT
ASSIGNED TO EXAMINER
Apr 20, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 17, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 13, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 9, 2020 REPR